Bristle myers squib And Fizer On Thursday, they said that they would start selling their blockbuster blood thinner, alikis directly to patients at a discount of more than 40%.
This step puts pressure on the pharmaceutical industry as Trump administration Drug price cutAnd threatens Impose sweeping tariff On pharmaceuticals imported in America
The new effort of the companies will bypass traditional middlemen, including pharmacy profit managers and insurers, to cut the drug’s monthly cost from a list price of approximately $ 606 to $ 346. Starting from 8 September, unlicensed, low and self-refusing patients will be able to buy medicines directly from the Elicks 360 support program, which will send their prescriptions directly to their homes.
But the concessional price of Elixis is still Average monthly out-of-packet cost more than nine times $ 38 paid by commercially insured patients is paid. The price under the new program is also much higher than the price of $ 231 per month, which Medicare interacted under the provision of inflation in the inflation of biden administration. The price of that conversation is scheduled to be effective next year.
The price of the conversation is what will pay for Medicare Eliccis, and it does not determine what the medicare patient will pay for the medicine anymore or in future, Bristol Myers Squib and Phiseer said in a joint statement. He said that the price of the conversation does not reflect “adequate clinical and economic value of this essential drug”.
More than 90% of Elixi recipes in the US are currently covered through insurance. But Bristol Myers Squib and Fizer said that the purpose of the new attempt is to expand access to treatment, reduce out-of-pocket costs for the patient and provide transparent pricing for a separate group of patients.
Chris Borner, CEO of Bristol Myers Squib, said, “This program directly saves patients and focuses on our constant focus on identifying innovative solutions that promote the best results for each individual, while prioritizing access to care.”
In a note on Thursday, Lerink Partners’ analyst David Reginger said that the step came in response to Trump’s plan to reduce the cost of American drug by adding the prices paid in other developed countries. chairman Put signature on An executive order on that plan in May.
Risinger stated that drug manufacturers already offer heavy discounts on Elicis for pharmacy profit managers, so the firm is not expected to create a “net pricing headwind” for Bristol Myers Squeb and Fizer.
